OBJECTIVES: This study evaluated the effects of gastrin messenger RNA (mRNA) down-regulation on growth of human pancreatic cancer. METHODS: Gastrin expression was examined in human pancreatic cancer cell lines by reverse transcriptase-polymerase chain reaction, and peptide expression was assessed by immunocytochemistry. Gastrin was down-regulated using either stable transfection of an antisense gastrin cDNA or 1 of 3 shRNA (short hairpin RNA) constructs. Tumor formation was evaluated after either subcutaneous or orthotopic injections into nude mice. The effect of nanoliposomes loaded with gastrin siRNA (small interfering RNA) was tested in mice bearing pancreatic tumors. RESULTS: Stable transfection of gastrin antisense or shRNAs into BxPC-3 cells resulted in clones with more than 90% reduction in gastrin mRNA. Tumor growth rate and incidence of metastases in both wild-type and transfected pancreatic cancer cells were directly proportional to the degrees of gastrin mRNA expression. Immunofluorescence analysis confirmed that gastrin peptide levels were decreased in antisense and shRNA tumors. Gastrin knockdown clones had lower Ki-67 and increased cleaved caspase-3 staining, consistent with known effects of gastrin on proliferation and apoptosis. Tumors in mice treated with gastrin siRNA were smaller than controls. CONCLUSIONS: These results suggest that RNAi targeting of gastrin could serve as an effective treatment for pancreatic cancer.
OBJECTIVES: This study evaluated the effects of gastrin messenger RNA (mRNA) down-regulation on growth of humanpancreatic cancer. METHODS:Gastrin expression was examined in humanpancreatic cancer cell lines by reverse transcriptase-polymerase chain reaction, and peptide expression was assessed by immunocytochemistry. Gastrin was down-regulated using either stable transfection of an antisense gastrin cDNA or 1 of 3 shRNA (short hairpin RNA) constructs. Tumor formation was evaluated after either subcutaneous or orthotopic injections into nude mice. The effect of nanoliposomes loaded with gastrin siRNA (small interfering RNA) was tested in mice bearing pancreatic tumors. RESULTS: Stable transfection of gastrin antisense or shRNAs into BxPC-3 cells resulted in clones with more than 90% reduction in gastrin mRNA. Tumor growth rate and incidence of metastases in both wild-type and transfected pancreatic cancer cells were directly proportional to the degrees of gastrin mRNA expression. Immunofluorescence analysis confirmed that gastrin peptide levels were decreased in antisense and shRNA tumors. Gastrin knockdown clones had lower Ki-67 and increased cleaved caspase-3 staining, consistent with known effects of gastrin on proliferation and apoptosis. Tumors in mice treated with gastrin siRNA were smaller than controls. CONCLUSIONS: These results suggest that RNAi targeting of gastrin could serve as an effective treatment for pancreatic cancer.
Authors: Joseph C Harris; Andrew D Gilliam; Andrew J McKenzie; Sean A Evans; Anna M Grabowska; Philip A Clarke; Daniel F McWilliams; Sue A Watson Journal: Cancer Res Date: 2004-08-15 Impact factor: 12.701
Authors: M H Tan; N J Nowak; R Loor; H Ochi; A A Sandberg; C Lopez; J W Pickren; R Berjian; H O Douglass; T M Chu Journal: Cancer Invest Date: 1986 Impact factor: 2.176
Authors: Gail L Matters; Christopher McGovern; John F Harms; Kevin Markovic; Krystal Anson; Calpurnia Jayakumar; Melissa Martenis; Christina Awad; Jill P Smith Journal: Int J Oncol Date: 2010-12-24 Impact factor: 5.650
Authors: Brian M Barth; Rahul Sharma; Erhan I Altinoğlu; Thomas T Morgan; Sriram S Shanmugavelandy; James M Kaiser; Christopher McGovern; Gail L Matters; Jill P Smith; Mark Kester; James H Adair Journal: ACS Nano Date: 2010-03-23 Impact factor: 15.881
Authors: Kristin K Fino; Gail L Matters; Christopher O McGovern; Evan L Gilius; Jill P Smith Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-03-22 Impact factor: 4.052
Authors: Jill P Smith; Shangzi Wang; Sandeep Nadella; Sandra A Jablonski; Louis M Weiner Journal: Cancer Immunol Immunother Date: 2017-10-17 Impact factor: 6.968
Authors: Gail L Matters; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Jiangang Liao; Brian M Barth; Mark Kester; Jill P Smith Journal: Dig Dis Sci Date: 2014-05-11 Impact factor: 3.199
Authors: Nicholas Osborne; Rebecca Sundseth; Julian Burks; Hong Cao; Xunxian Liu; Alexander H Kroemer; Lynda Sutton; Allen Cato; Jill P Smith Journal: Cancer Immunol Immunother Date: 2019-09-24 Impact factor: 6.968
Authors: Jill P Smith; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Qing Zhong; Jiangang Liao; Alfredo A Molinolo; J Silvio Gutkind; Gail L Matters Journal: Pancreas Date: 2014-10 Impact factor: 3.327